Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The event will take place at the Lotte New York Palace in New York.
The company's management will conduct a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will engage in one-on-one investor meetings. Interested parties can access a live audio webcast of the presentation through Erasca.com/events, where an archived replay will remain available for 30 days following the event.
Erasca (Nasdaq: ERAS), un'azienda clinica di oncologia di precisione specializzata nello sviluppo di terapie per i tumori guidati dal percorso RAS/MAPK, ha annunciato la sua prossima partecipazione al Guggenheim Securities SMID Cap Biotech Conference. L'evento si terrà presso il Lotte New York Palace a New York.
La direzione dell'azienda condurrà un fireside chat giovedì 6 febbraio 2025, alle 9:30 ora orientale e avrà incontri individuali con gli investitori. Le parti interessate possono accedere a una diretta audio della presentazione attraverso Erasca.com/events, dove una registrazione archiviata rimarrà disponibile per 30 giorni dopo l'evento.
Erasca (Nasdaq: ERAS), una empresa de oncología de precisión en etapa clínica enfocada en desarrollar terapias para cánceres impulsados por la vía RAS/MAPK, ha anunciado su próxima participación en la Guggenheim Securities SMID Cap Biotech Conference. El evento se llevará a cabo en el Lotte New York Palace en Nueva York.
La gerencia de la empresa realizará un fireside chat el jueves 6 de febrero de 2025, a las 9:30 am hora del Este y participará en reuniones individuales con inversores. Las partes interesadas podrán acceder a una transmisión en vivo de audio de la presentación a través de Erasca.com/events, donde una repetición archivada estará disponible durante 30 días después del evento.
에라스카 (Nasdaq: ERAS), RAS/MAPK 경로에 의해 유도되는 암 치료제를 개발하는 데 집중하는 임상 단계의 정밀 종양학 회사가 구겐하임 증권 SMID Cap 생명공학 컨퍼런스에 참여할 예정이라고 발표했습니다. 이 행사는 뉴욕의 롯데 뉴욕 팰리스에서 열릴 예정입니다.
회사의 경영진은 2025년 2월 6일 목요일 오전 9시 30분 동부 표준시에 진행되는 파이어사이드 챗을 진행하며, 투자자들과 일대일 회의를 가질 것입니다. 관심 있는 당사자들은 Erasca.com/events를 통해 발표의 실시간 오디오 웹캐스트에 액세스할 수 있으며, 이벤트 종료 후 30일 동안 아카이브된 재생이 제공될 것입니다.
Erasca (Nasdaq: ERAS), une entreprise d'oncologie de précision en phase clinique axée sur le développement de thérapies pour les cancers induits par la voie RAS/MAPK, a annoncé sa prochaine participation à la Guggenheim Securities SMID Cap Biotech Conference. L'événement se déroulera au Lotte New York Palace à New York.
La direction de l'entreprise animera un fireside chat le jeudi 6 février 2025 à 9h30 heure de l'Est et participera à des réunions individuelles avec les investisseurs. Les parties intéressées peuvent accéder à un webinaire audio en direct de la présentation via Erasca.com/events, où un enregistrement archivé sera disponible pendant 30 jours suivant l'événement.
Erasca (Nasdaq: ERAS), ein Unternehmen für präzise Onkologie in der klinischen Phase, das sich auf die Entwicklung von Therapien für RAS/MAPK-Wege-gesteuerte Krebserkrankungen konzentriert, hat seine bevorstehende Teilnahme an der Guggenheim Securities SMID Cap Biotech Conference angekündigt. Die Veranstaltung findet im Lotte New York Palace in New York statt.
Die Unternehmensführung wird am Donnerstag, den 6. Februar 2025, um 9:30 Uhr Eastern Time ein Fireside Chat durchführen und sich in Einzelgespräche mit Investoren engagieren. Interessierte Parteien können über Erasca.com/events auf ein Live-Audio-Webcast der Präsentation zugreifen, während eine archivierte Wiederholung 30 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
FAQ
When is Erasca (ERAS) presenting at the Guggenheim Securities SMID Cap Biotech Conference 2025?
Where can investors watch Erasca's (ERAS) Guggenheim Securities conference presentation?
What type of cancer treatments is Erasca (ERAS) developing?
Where is the Guggenheim Securities SMID Cap Biotech Conference 2025 being held?
